Company / Revenue
Xeris Biopharma Holdings, Inc. Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$291.8M
FY2025
5-year range
$49.6M / $291.8M
FY2021-FY2025
Trend
+43.7%
vs FY2024
Sector context
#78 of 155
Health Care
What the data says
At $292M, Xeris Biopharma Holdings, Inc.'s revenue ranks #78 of 155 in the Health Care sector. Revenue has increased for 3 consecutive years, from $50M in FY2022 to $292M in FY2025.
Based on SEC 10-K filings.
$292M in FY2025 with a 5-year CAGR of +70.2%.
Improved from $164M to $292M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +80.5%
- 5-Year CAGR
- +70.2%
- 10-Year CAGR
- -
Sector benchmark
#78 of 155 in Health CareTop 50% of 155This company $291.8M Sector average $4.5B
▼
-93.5% below sector average
Key checks
Key Insights
- Xeris Biopharma Holdings, Inc.'s revenue has grown for 3 consecutive years.
- 5-year CAGR of +70.2%, indicating consistent growth.
- In FY2025, revenue increased 43.7% year-over-year.
- Ranks #78 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $291.8M | +43.7% |
| FY2024 | $203.1M | +23.9% |
| FY2023 | $163.9M | +230.5% |
| FY2022 | $49.6M | +0.0% |
| FY2021 | $49.6M | +142.7% |
| FY2020 | $20.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026